Combining SGLT2 inhibitor and GLP-1 agonist: exaggerated weight loss in a morbidly obese patient with type 2 diabetes

Authors

  • Kg Nilwala U Jayasinghe Beta Cell Diabetes Centre, Chelsea & Westminster Hospital, London, UK
  • Veronica J Greener Beta Cell Diabetes Centre, Chelsea & Westminster Hospital, London, UK
  • Michael D Feher Beta Cell Diabetes Centre, Chelsea & Westminster Hospital, London, UK

DOI:

https://doi.org/10.15277/bjd.2016.092

References

McGovern AP, Dutta N, Munro N, Watters K, Feher M. Dapagliflozin: clinical practice compared with pre-registration trial data. Br J Diabetes Vasc Dis 2014;14:138-43. http://dx.doi.org/10.15277/bjdvd.2014.047

McGovern AP, Munro N, Watters K, Feher M. Profound weight reduction with GLP‐1 agonist therapy: a delayed hyper‐response. Pract Diabetes 2014;31:286-a.

Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide. Int J Obes 2012;36:843–54. http://dx.doi.org/10.1038/ijo.2011.158

Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes 2013;37:1443–51. http://dx.doi.org/10.1038/ijo.2013.120

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771. http://dx.doi.org/10.1136/bmj.d7771

Jendle J, Nauck M, Matthews D, et al. Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163-72. http://dx.doi.org/10.1111/j.1463-1326.2009.01158.x

Marre M, Shaw J, Brändle M, et al. Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD‐1 SU). Diabet Med 2009;26:268-78. http://dx.doi.org/10.1111/j.1464-5491.2009.02666.x

Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2011;97:1020-31. http://dx.doi.org/10.1210/jc.2011-2260

Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24. http://dx.doi.org/10.2337/dc10-0612

Kasichayanula S, Liu X, Shyu W, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011;13:47-54. http://dx.doi.org/10.1111/j.1463-1326.2010.01314.x

Jensterle M, Pirs B, Goricar K, Dolzan V, Janez A. Genetic variation in GLP1 receptor is associated with interindividual differences in weight lowering potential of liraglutide in obese women with PCOS. 17th European Congress of Endocrinology, Endocrine Abstracts, 2015. http://dx.doi.org/10.1530/endoabs.37.ep590

Downloads

Published

2016-09-18

Issue

Vol. 16 No. 3 (2016)

Section

Case Reports

License

Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.